NLS Pharmaceutics Ltd. (NASDAQ:NCEL – Get Free Report)’s share price was up 3.2% during mid-day trading on Thursday . The company traded as high as $3.39 and last traded at $3.27. Approximately 17,891 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 62,883 shares. The stock had previously closed at $3.17.
NLS Pharmaceutics Price Performance
The business’s fifty day simple moving average is $3.15 and its 200-day simple moving average is $2.89.
Insiders Place Their Bets
In other news, Director Olivier Samuel purchased 81,818 shares of the business’s stock in a transaction on Monday, April 27th. The shares were acquired at an average price of $2.75 per share, with a total value of $224,999.50. Following the acquisition, the director directly owned 81,818 shares in the company, valued at approximately $224,999.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michel Revel bought 54,545 shares of the company’s stock in a transaction dated Monday, April 27th. The stock was bought at an average cost of $2.75 per share, with a total value of $149,998.75. Following the completion of the transaction, the director owned 957,530 shares in the company, valued at approximately $2,633,207.50. This trade represents a 6.04% increase in their position. The disclosure for this purchase is available in the SEC filing. 16.40% of the stock is owned by company insiders.
NLS Pharmaceutics Company Profile
NLS Pharmaceutics (NASDAQ: NCEL) is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, with additional operations in the United States. The company focuses on the development of small-molecule therapies designed to address disorders of the circadian rhythm and sleep-wake cycle. It leverages proprietary controlled-release and receptor-targeting approaches to optimize drug exposure over a 24-hour period.
The core of NLS Pharmaceutics’ pipeline consists of novel melatonin receptor agonists aimed at treating rare and orphan sleep disorders such as non-24-hour sleep-wake disorder and idiopathic hypersomnia.
Featured Stories
- Five stocks we like better than NLS Pharmaceutics
- Time to Sell? 3 Winners With Fading Technical Momentum
- Why These 2 Hotel Stocks Are Beating Travel Peers
- This Energy Stock Has Quietly Soared 130% in a Year
- 3 ‘Boring’ Dividend Stocks With Tasty Technical Setups
Receive News & Ratings for NLS Pharmaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NLS Pharmaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
